U.S. officials see the deal as a threat to NATO, for which Turkey provides the second-largest military.World Politicsread more
Google's services have been blocked in China for several years, but the company still has a business there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
China may have signaled it's going more hard-line on trade, but it could be a good thing, former U.S. negotiator Clete Willems told CNBC.World Economyread more
Facebook's cryptocurrency project has already been met with skepticism from policymakers around the world.Technologyread more
As China's economic growth declines, some analysts say Beijing may have to spend more on infrastructure, adding to concerns about high debts.China Economyread more
After years of speculation, Neuralink, the brain-machine interface start-up co-founded by Elon Musk, started talking directly to the public on Tuesday.Technologyread more
United's Optum is launching a new partnership with John Muir Health aimed at helping the small northern California hospital operator become more competitive with its larger...Health and Scienceread more
"The charts, as interpreted by Carley Garner, suggest that the upside in the stock market has gotten more limited," Jim Cramer says.Mad Money with Jim Cramerread more
John Paul Stevens, who served on the Supreme Court for nearly 35 years and became its leading liberal, has died.Politicsread more
Aarti Borkar from IBM Security says artificial intelligence bias can exist at three levels: the program, the data and the people who design those AI systems.Cybersecurityread more
A key read on the industry, the Architecture Billings Index, fell into negative territory in June, according to the American Institute for Architects. Inquiries for new...Real Estateread more
The pharmaceutical company boss under fire for increasing the price of the drug Daraprim by more than 5,000 percent said Tuesday he will lower the cost of the life-saving medication.
Martin Shkreli did not say what the new price would be, but expected a determination to be made over the next few weeks.
He told NBC News that the decision to lower the price was a reaction to outrage over the increase in the price of the drug from $13.50 to $750 per pill.
"Yes it is absolutely a reaction — there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people," Shkreli, 32, said.
Turing Pharmaceuticals of New York bought the drug from Impax Laboratories in August for $55 million and raised the price. Shkreli said Tuesday the price would be lowered to allow the company to break even or make a smaller profit.
Daraprim fights toxoplasmosis. The infection is particularly dangerous for people who have weakened immune systems, like AIDS patients, as well as for pregnant women, according to the Centers for Disease Control and Prevention.
The New York Times first reported the price increase on Sunday.
Shkreli, the founder and CEO of Turing, had said the money from the increase would be used to develop better treatment for toxoplasmosis that have fewer side effects. He told NBC News Tuesday that drugs like Daraprim will not exist if small companies cannot get a return on their investment.
"It's very easy to see a large drug price increase and say 'Gosh, those people must be gouging.' But when you find out that the company is not really making any money, what does that mean?" Shkreli said in a phone interview with NBC News Tuesday. "It's very hard stuff to understand."
The Infectious Diseases Society of America and the HIV Medicine Associationobjected to the price increase, saying "this cost is unjustifiable for the medically vulnerable patient population in need of this medication."
Democratic presidential candidate Hillary Clinton was among those who expressed outrage over the price increase. On Tuesday she outlined a plan she said would limit how much patients have to pay out of pocket for medications each month.
"I think in the society we live in today it's easy to want to villainize people, and obviously we're in an election cycle where this is very, very tough topic for people and it's very sensitive. And I understand the outrage," Shkreli said.
Shkreli said on Twitter Tuesday afternoon that he planned to "set the record straight on misconceptions and announce some adjustments to our plan." He planned to make his Twitter account private after that.
Shkreli acknowledged that the cost to produce the drug is low — but he said that doesn't take into account "the quality control, the regulatory costs, and all of the other things that come with having a drug company."
"We'll know in several weeks how profitable the drug is, if it at all," Shkreli said in the NBC News interview. "It may turn out that's it not even profitable at all, even at this price."
(UPDATE AND CORRECTION: This story was updated throughout. An earlier version incorrectly stated the expected adjustment to the price of Daraprim.)